Physician profile
David L Carr Locke
NPI 1417913609
$2,011,634.17
in general payments reported to CMS, 2019-2025
27 companies · $342K in 2025
The $342K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322K · 2020: $259K · 2021: $305K · 2022: $301K · 2023: $156K · 2024: $327K · 2025: $342K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $810K · Food and Beverage: $6,836 · Consulting Fee: $4,350 · Travel and Lodging: $3,792 · Education: $32.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $809,748.72 |
| Food and Beverage | $6,836.21 |
| Consulting Fee | $4,350.00 |
| Travel and Lodging | $3,792.19 |
| Education | $32.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Endoscopy | $1,962,905.31 | 2019-2025 | |
| Boston Scientific Corporation | $38,258.78 | 2019-2025 | Spyglass, Apollo Esg System, Axios |
| Steris Corporation | $2,557.29 | 2025 | |
| W. L. Gore & Associates, INC. | $2,403.50 | 2019 | |
| Conmed Corporation | $972.11 | 2019-2024 | Conmed Biliary, Conmed Gastrostomy, Conmed Hemostasis |
| Olympus America INC. | $643.96 | 2019-2025 | Single Use Repositionable Clip, Gastrointestinal Videoscope, Evis Exera III Colonovideoscope |
| Abbvie INC. | $551.30 | 2022-2025 | Rinvoq |
| Medtronic, INC. | $424.09 | 2021-2025 | Gi Genius, Sharkcore |
| Mauna Kea Technologies, INC. | $354.82 | 2019-2023 | |
| Galvanize Therapeutics, INC | $307.12 | 2023-2025 | Aliya System |
| Micro-Tech Endoscopy USA, INC. | $278.05 | 2019 | |
| Cook Medical LLC | $264.92 | 2023 | Echotip |
| Takeda Pharmaceuticals U.S.A., INC. | $228.82 | 2022-2025 | Entyvio, Gattex |
| Fujifilm Healthcare Americas Corporation | $214.80 | 2024 | Fujifilm |
| Janssen Biotech, INC. | $211.09 | 2025 | Tremfya |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien Lp | $210.59 | 2019 | |
| Endogastric Solutions, INC | $180.20 | 2019 | |
| Lumendi LLC | $154.00 | 2020 | |
| Merit Medical Systems INC | $129.49 | 2025 | Esophyx |
| Qol Medical, LLC | $124.99 | 2021 | |
| Celltrion USA INC. | $76.47 | 2024-2025 | Vegzelma, Zymfentra |
| Celgene Corporation | $63.54 | 2023 | Zeposia |
| Pentax of America, INC. | $36.38 | 2023 | Inspira |
| Merck Sharp & Dohme LLC | $23.60 | 2024 | Zerbaxa, Recarbrio, Dificid |
| Amgen INC. | $21.12 | 2023 | Amjevita, Avsola |
| Lilly USA, LLC | $19.18 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.65 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Carr Locke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.